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Abstract
Propofol is a widely used intravenous general anesthetic. Propofol-induced unconsciousness in
humans is associated with inhibition of thalamic activity evoked by somatosensory stimuli.
However, the cellular mechanisms underlying the effects of propofol in thalamic circuits are largely
unknown. We investigated the influence of propofol on synaptic responsiveness of thalamocortical
relay neurons in the ventrobasal complex (VB) to excitatory input in mouse brain slices, using both
current- and voltage-clamp recording techniques. Excitatory responses including EPSP temporal
summation and action potential firing were evoked in VB neurons by electrical stimulation of
corticothalamic fibers or pharmacological activation of glutamate receptors. Propofol (0.6 – 3 µM)
suppressed temporal summation and spike firing in a concentration-dependent manner. The
thalamocortical suppression was accompanied by a marked decrease in both EPSP amplitude and
input resistance, indicating that a shunting mechanism was involved. The propofol-mediated
thalamocortical suppression could be blocked by a GABAA receptor antagonist or chloride channel
blocker, suggesting that postsynaptic GABAA receptors in VB neurons were involved in the
shunting inhibition. GABAA receptor-mediated inhibitory postsynaptic currents (IPSCs) were
evoked in VB neurons by electrical stimulation of the reticular thalamic nucleus. Propofol markedly
increased amplitude, decay time, and charge transfer of GABAA IPSCs. The results demonstrated
that shunting inhibition of thalamic somatosensory relay neurons by propofol at clinically relevant
concentrations is primarily mediated through the potentiation of the GABAA receptor chloride
channel-mediated conductance, and such inhibition may contribute to the impaired thalamic
responses to sensory stimuli seen during propofol-induced anesthesia.
Background
General anesthesia consists of five distinct components:
analgesia, amnesia, unconsciousness, immobility, and
blunted autonomic responsiveness [1,2]. While the spinal
cord is considered to be the anatomic substrate for anes-
thetic-induced immobility in response to noxious stimu-
lation [3,4], the anatomic foundations for the other
components are less well established. The thalamus is a
key integrative structure for somatosensory transmission
[5] and, in particular, ascending nociceptive information
processing [6,7].
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Excitatory input regulates the functional state of thalamic
neurons, and such input is provided by both ascending
activating systems in the brain stem and hypothalamus
and the descending (corticothalamic) pathway [8]. Corti-
cothalamic axons outnumber thalamocortical axons by
~10-fold [9], and activation of this massive descending
input depolarizes thalamic neurons, including thalamo-
cortical relay neurons in the ventrobasal (VB) complex,
facilitates relay spike transfer, and/or alters the response
mode of thalamic relay neurons [10-18]. Inhibitory con-
trol of thalamocortical neurons in rodents is provided
exclusively by GABAergic neurons in the reticular tha-
lamic nucleus [8,19], and such control is mediated by dis-
ynaptic (cortex to RTN to VB) and monosynaptic (RTN to
VB) connections.
Propofol (2-6-di-isopropylphenol) is a widely used intra-
venous anesthetic with a distinct chemical structure, and
is a potent allosteric modulator of GABAA  receptors
[20,21]. Recent clinical findings have revealed possible
sites of propofol-elicited anesthetic action in the human
brain [22,23]. During propofol-induced unconsciousness
in humans, somatosensory-evoked neuronal activity in
the cortex and the thalamus is markedly decreased
[24,25]. In vivo extracellular recordings have also demon-
strated that propofol suppresses field potentials in the rat
thalamus and cortex, with more prominent effects in the
cortex [26]. However, the cortical suppression may reflect
anesthetic actions on projection neurons located else-
where, especially in the thalamus [22,27]. A significant
limitation to the in vivo data from anesthetized animals is
the use of "background anesthesia" (typically induced by
urethane, sodium pentobarbital or a ketamine/xylazine
combination) for baseline recordings; such "background
anesthesia" makes it impossible to interpret the data sub-
sequently obtained with the anesthetic(s) of interest [28].
Propofol modulates GABA-evoked currents in heterolo-
gously expressed GABAA receptors containing an α1, α2,
α4, α5, α6, δ or γ2L subunit [29-37]. Behavioral studies
suggest that the β3 subunit is important in mediating pro-
pofol-induced unconsciousness and immobility [38],
while the β2 subunit may mediate sedation [39]. Propofol
potentiation of GABA-evoked currents in heterologously
expressed GABAA receptors is independent of the β1 sub-
unit [29].
Cumulative data from a number of studies using a variety
of techniques (including electrophysiology, gene knock-
out, immunohistochemistry, immunoprecipitation, and
ligand binding) suggest that VB neurons primarily express
synaptic  α1β2γ2 and α4β2γ2 and extrasynaptic α4β2δ
GABAA receptors while RTN neurons are likely to preferen-
tially express synaptic α3β3γ2 GABAA  receptors, with
denser GABA receptor expression in VB than in RTN [40-
58]. These data further support the hypothesis that the
thalamus represents an important anatomic target for
propofol.
The thalamus is central to the processing and transfer of
nearly all sensory information that ultimately reaches the
cortex, with the exception of olfaction, whose signals pass
to the cortex without thalamic relay. Clinical observations
strongly suggest that thalamic neuronal circuits are impor-
tant targets for propofol. The effects of propofol at the cel-
lular and synaptic levels in the thalamus are largely
unknown, however. Therefore, we investigated the effect
of propofol on synaptic integration and action potential
firing in response to corticothalamic pathway stimulation
in thalamocortical relay neurons in brain slices, using
both current- and voltage-clamp recording techniques.
The results demonstrated that propofol inhibited VB neu-
rons by potentiating GABAA-receptor chloride channel-
mediated currents. Preliminary results have been pub-
lished in abstract form [59]
Results
Under low power magnification, the VB was easily dis-
cerned in brain slices (Fig. 1A), and with the aid of IR-DIC
optics, neurons in VB were readily identified (not shown).
VB neurons generally showed a large, slow depolarizing
sag and slow after-burst depolarization (ADP, Fig. 1B) in
response to deep hyperpolarizing current steps [17]. Bio-
cytin labeling in a subset of cells identified the recording
site relative to anatomical landmarks (not shown).
Propofol suppresses temporal summation in VB neurons
The responses of VB neurons in vivo to somatosensory
stimuli depend on the state of arousal, and the functional
state is linked to neuronal depolarization levels that can
be regulated by corticothalamic excitatory (CT) input [8].
CT excitatory synapses in VB exhibit prominent fre-
quency-dependent summation [13,16,60-62]. We there-
fore examined the effect of propofol on CT-evoked
temporal summation in VB neurons. Repetitive stimula-
tion (33 Hz, 5 pulses) of the white matter gave rise to
incremental excitatory postsynaptic potentials (EPSPs)
that showed summation without apparent inhibitory
postsynaptic potentials (IPSPs) at membrane potentials of
-58 to -54 mV (Fig. 1C), identical to those seen by others
[60,63]. CT-evoked EPSPs had an average latency of 3.2 ±
0.3 ms (n = 55). In some cases, summation could lead to
spike firing at the 5th EPSP (not shown); for ease of com-
parison, we only analyzed those responses without spikes.
CT-evoked EPSPs could be abolished by CNQX and AP5
(Fig. 1D), consistent with frequency-dependent facilita-
tion mediated by both NMDA and non-NMDA receptors
[64]. The degree of CT EPSP summation increased with
increasing stimulation frequency, with a dramaticMolecular Pain 2005, 1:2 http://www.molecularpain.com/content/1/1/2
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Synaptic temporal summation in VB relay neurons Figure 1
Synaptic temporal summation in VB relay neurons. A: a photomicrograph of a live brain slice containing the ventroba-
sal (VB) complex, reticular thalamic nucleus (RTN), and other regions with which VB has synaptic connections. Thalamocorti-
cal slices were cut at 55° (Agmon and Connors, 1991). B: both tonic and rebound burst firing patterns were initiated in a VB 
neuron with intracellular current pulses (protocol not shown). A distinct membrane voltage response is characterized by a 
prominent sag and after-depolarization potential (ADP) in response to hyperpolarizing current pulses. The value to the left of 
the trace indicates membrane potential (mV) here and throughout. C: EPSPs showing temporal summation were evoked by 
extracellular stimulation of corticothalamic fibers in the white matter (a train of 5 pulses, 33 Hz, 0.15 ms). D: evoked EPSPs 
could be blocked by CNQX/AP5. E: group data demonstrating that EPSP temporal summation is frequency-dependent (n = 
10).
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increase (400–480%) in summation at 33–40 Hz (Fig.
1E).
We next examined the effect of propofol on temporal
summation of EPSPs evoked at 33 Hz. Bath application of
propofol (3 µM) hyperpolarized the MP by 3–5 mV, and
markedly suppressed the magnitude of CT EPSP summa-
tion (102.4 ± 18.5%) in 15 relay neurons tested (Fig. 2A),
and the degree to which propofol decreased summation
was concentration-dependent (Fig. 2D). Propofol also
decreased EPSP amplitude by 30–75% and input resist-
ance by 35.2 ± 4.1% (P < 0.05, Fig. 2B), consistent with
shunting inhibition. In addition, small IPSPs were evoked
during propofol application (Fig. 2, middle).
To determine whether propofol-modulation of GABAA
receptors contributed to the decrease in summation and
input resistance, the experiments were repeated in the
presence of GABAA receptor chloride channel blockade. In
another group of cells (n = 10), bicuculline (10 µM) alone
had no significant effect on CT EPSP summation evoked
by the same repetitive stimulation as above (Fig. 2C left
panel), and a similar response was observed for picrotoxin
(100 µM, not shown). Our data were nearly identical to
those observed by others [60]. The failure of either
GABAA-R blocker to markedly increase temporal summa-
tion was likely due to the fact that disynaptic inhibition
generated within the cortex-RTN-VB circuit was markedly
reduced during repetitive stimulation, which resulted in
excitatory response only [60]. Propofol, when co-applied
with bicuculline, failed to decrease temporal summation
(Fig. 2C–D), indicating that GABAA  receptor-mediated
shunting inhibition was involved. The effects of propofol
on integrative properties of synaptic responses are sum-
marized in Table 1.
Propofol decreases spike firing evoked at corticothalamic 
synapses in VB
As shown above, propofol suppressed glutamatergic exci-
tatory subthreshold responses (EPSPs) via modulation of
GABAA  receptor chloride channels. Such suppression
might reduce spike generation in response to excitatory
synaptic input. We therefore investigated whether propo-
fol could affect corticothalamic-evoked spike firing. VB
neurons were held at depolarized membrane potentials (-
51 to -48 mV); stimulation (10–15 Hz) of CT fibers
evoked single spike firing in 25 neurons tested (Fig. 3A)
with an average latency of 4.2 ± 1.1 ms, and evoked spikes
could be blocked by TTX (not shown). These observations
are consistent with other reports [13,60]. Bath application
of propofol significantly decreased the number of evoked
spikes in a concentration-dependent manner (Fig. 3B and
3D). The effect of propofol could be completely blocked
by bicuculline (Fig. 3C), confirming the involvement of
GABAA receptors.
Propofol inhibits tonic firing by increasing GABAergic input
Thalamocortical neurons in vivo fire tonic single spikes
during the waking state or in response to excitatory synap-
tic stimuli [8]. In brain slices, however, these neurons gen-
erally do not fire spontaneously; a sustained single spike
firing pattern can be induced by pharmacological activa-
tion of metabotropic glutamate receptors (mGluRs) with
trans-ACPD [63]. Since propofol at concentrations less
than 10 µM does not affect glutamatergic transmission
[65-70], we tested whether propofol could inhibit trans-
ACPD-induced spike firing through GABAergic mecha-
nisms. Bath application of trans-ACPD (100 µM) gradu-
ally depolarized the membrane of VB relay neurons by 14
± 4 mV (n = 12) from resting membrane potentials, and
resulted in the generation of sustained, tonic spike firing
(Fig. 4Atop), an effect similar to that seen in the dorsal lat-
eral geniculate nucleus of the thalamus [63]. After a stable
tonic, firing pattern was obtained during ACPD applica-
tion (> 10 min), propofol was added (Fig. 4Amiddle). Pro-
pofol markedly decreased both firing rate, and apparent
input resistance (P < 0.05, n = 8, one-way ANOVA, vs.
control, traces for measuring input resistance not shown).
Although action potential firing in VB neurons was inhib-
ited, RTN neurons continued to fire spikes, as evidenced
by the presence of spontaneous IPSPs (sIPSPs, Fig. 4B).
The sIPSPs appeared to result from propofol-induced acti-
vation of RTN neurons, rather than direct excitation of
RTN by trans-ACPD, as few, if any, sIPSPs occurred prior
to propofol application. The propofol-induced suppres-
sion could be blocked by subsequent addition of bicucul-
line (Fig. 4Abottom), indicating that the suppression of VB
neuron spike firing was mediated by GABAA receptors.
Group data demonstrated that propofol significantly sup-
pressed tonic spike firing initiated by pharmacological
activation of mGluRs in a concentration-dependant man-
ner (Fig. 4C, P < 0.001, n = 8, one-way ANOVA, vs. con-
trol). Propofol hyperpolarized the membrane potential,
and the hyperpolarization persisted throughout propofol
application (Fig. 4A, middle). This effect could be reversed
by addition of bicuculline (Fig. 4A, bottom) or picrotoxin
(not shown). Group data (Fig. 4D) demonstrated that
propofol significantly hyperpolarized the membrane
potential from -53.7 ± 1.6 to -65 ± 2.9 mV (P < 0.01, same
data set as above), strongly suggesting that propofol likely
potentiated the tonic GABAA receptor-mediated current.
In another subgroup of cells (n = 4, not illustrated), bicu-
culline alone was added after ACPD induced the tonic fir-
ing rate, followed by co-application of propofol (3 µM)
and bicuculline. Bicuculline alone increased the firing rate
by 16.8 ± 3.2% and the addition of propofol failed to sup-
press the firing rate.Molecular Pain 2005, 1:2 http://www.molecularpain.com/content/1/1/2
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Propofol suppresses temporal summation via a shunting mechanism Figure 2
Propofol suppresses temporal summation via a shunting mechanism. A: (left) control EPSP summation was recorded 
as described for Fig. 1C. Bath application of propofol (3 µM, 20 min) markedly decreased EPSP amplitude and summation (mid-
dle). Overlay (right) comparing EPSPs in the absence and presence of propofol. B: overlay (left) comparing voltage responses 
elicited by a hyperpolarizing current pulse (-60 pA, 500 ms, not shown) in the absence (control, thin line) and presence of pro-
pofol (thick line) in the same neuron as in A. Note that propofol decreased apparent input resistance. Bar graph (right) showing 
that propofol significantly decreases input resistance. *: P < 0.05, n = 15. Time scales: 100 ms for A and 300 ms for B. C: con-
trol EPSPs were recorded from a different VB neuron. Overlay (left) comparing EPSPs in the absence (control) and presence of 
the GABAA antagonist bicuculline (10 µM). Overlay (right) comparing EPSPs in the presence of bicuculline alone and bicuculline 
+ propofol (3 µM). In the presence of bicuculline, propofol had no significant effect on temporal summation, indicating propo-
fol-elicited shunting inhibition was mediated by GABAA receptors in VB neurons. D: group data showing that propofol 
decreases temporal summation through potentiation of GABAA receptors. *: P < 0.05, one-way ANOVA, vs. control. n = 15/
each group. prop = propofol (0.6, 0.3 µM), bic = bicuculline (10 µM).
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Propofol enhances GABAA receptor-mediated currents
Our data strongly suggested that propofol-elicited inhibi-
tion of VB neurons was primarily mediated through
potentiation of the GABAA receptor Cl- channel current;
this possibility was directly investigated using voltage-
clamp recordings. Electrical stimulation of RTN evoked
fast unitary IPSCs (eIPSCs) in relay neurons (the mem-
brane potential clamped at -60 mV), with an average
latency of 2.4 ± 0.8 ms (Fig. 5A). The eIPSC amplitude was
685 ± 28 pA (n = 30), and the two-exponential decay time
(10–90%) was 16.2 ± 2.2 ms. Bath application of propo-
fol increased current amplitude and prolonged current
decay time (Fig. 5A–B), and the propofol-potentiated cur-
rent could be completely abolished by picrotoxin (100
µM), indicating that the response was mediated by GABAA
receptor chloride channels (Fig. 5C). Inhibitory efficacy of
IPSCs can be estimated by calculating total Cl- charge
transfer [44]. The efficacy of the eIPSC in control was 1.2
± 0.8 pC, equivalent to 7.2 × 106 Cl- ion transfer. Group
data demonstrated that propofol increased eIPSC ampli-
tude, decay time, and charge transfer in a concentration-
dependent manner (Fig. 5D–F).
Discussion
The present study demonstrated for the first time that the
intravenous anesthetic propofol, at clinically relevant con-
centrations, suppressed corticothalamic-evoked EPSP
temporal summation and action potential firing in tha-
lamic somatosensory relay neurons in VB in vitro. The
importance of corticothalamic excitatory input in the reg-
ulation of thalamic information processing and transfer
has been stressed by recent evidence from in vivo and in
vitro experiments. For example, activation of corticotha-
lamic input facilitates single spike firing in thalamocorti-
cal neurons [13,64], and alters thalamocortical responses
to peripheral sensory stimuli [71-73]. In vivo studies in
humans have shown that propofol, at plasma levels suffi-
cient to produce unconsciousness, suppressed nociceptive
[25] and non-nociceptive stimulus-induced increases in
thalamic blood flow [24], indicating that thalamic activity
was decreased. Our data provide unambiguous support
for the hypothesis that propofol disrupts neuronal activity
and synaptic transmission in the thalamus.
The thalamus is an important propofol target-site
Propofol-induced unconsciousness in humans is accom-
panied by thalamic inhibition of somatosensory-evoked
activity [25] suggesting that such inhibition may play an
important role in contributing to general anesthesia. Evi-
dence supporting this assumption is the fact that propo-
fol, at clinically relevant concentrations, consistently
suppressed firing activity in all thalamic neurons tested
here. Neurons in other brain areas, however, are relatively
insensitive to propofol even at very high concentrations.
For example, propofol potentiated GABAA receptor-elic-
ited synaptic responses at 50 – 500 µM in the hippocam-
pus [70,74], enhanced GABA-elicited inhibition at 50 µM
in the olfactory cortex [75], and suppressed spike firing at
30 – 100 µM in the locus coeruleus [76]. Therefore, our
data demonstrate that the corticothalamic circuit is a
highly sensitive target for propofol.
Significance of propofol-induced suppression of thalamic 
excitatory responses
The transmission of sensory information through tha-
lamic relay neurons to the cerebral cortex is state-depend-
ent: transmission is reduced during slow wave sleep or
drowsiness, and is enhanced during the waking state [8].
These changes in thalamic excitability are linked to depo-
larization of relay neurons, which is primarily regulated
by corticothalamic excitatory input, or feedback [13]. Cor-
ticothalamic projection neurons in the cortex fire high-fre-
quency single and burst spikes in vivo, and such excitatory
input can readily lead to temporal summation in thalamic
target neurons [8]. Here, we clearly demonstrated that cor-
ticothalamic-evoked temporal summation and action
potential firing were markedly suppressed during propo-
fol application.
A sustained, tonic, firing pattern in thalamic neurons is
prevalent during the waking state [8,13]; such a firing
activity is lacking in brain slices. Thus, the metabotropic
Table 1: Effects of propofol on integrative properties of evoked EPSPs in thalamic VB neurons.
Slope (mV/ms) 1/2 width (ms) Decay time (ms)
control 1.8 ± 0.4 14.5 ± 2.6 13.2 ± 2.8
propofol 1.6 ± 0.4 6.3 ± 0.4** 16.3 ± 3.2*
+ bicuculline 1.9 ± 0.5 13.5 ± 2.1 12.2 ± 2.4
EPSPs are evoked by extracellular stimulation of corticothalamic fibers (a train of 5 pulses, 0.15 ms, 33 Hz). Data are derived from experiments as 
described in Fig. 2. Slope (dv/dt) representing depolarization rate is measured from the rising phase (20–80%) of the first EPSP. 1/2 width is 
measured at 50% of peak amplitude; decay time (20–80%) representing repolarization rate is measured from the falling phase of the fifth EPSP. *, P 
< 0.05. **, P < 0.001, vs. control.Molecular Pain 2005, 1:2 http://www.molecularpain.com/content/1/1/2
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Propofol decreases corticothalamic-evoked spike firing in VB neurons Figure 3
Propofol decreases corticothalamic-evoked spike firing in VB neurons. A: action potentials were evoked by cortico-
thalamic (CT) stimulation in a VB neuron under control conditions. B: bath-application of propofol (0.6 µM) suppressed spike 
generation, and this suppression could be blocked by 10 µM bicuculline (C). Propofol was applied 20 min before the trace in 
(B) was recorded. D: bar graph indicates that propofol suppressed successful synaptic transmission (% suppression) at CT syn-
apses in VB in a concentration-dependent manner. *, P < 0.05, one-way ANOVA, vs. control, n = 15.
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Propofol suppresses trans-ACPD-evoked tonic spike firing in VB neurons Figure 4
Propofol suppresses trans-ACPD-evoked tonic spike firing in VB neurons. A: bath application of the metabotropic 
glutamate receptor agonist trans-ACPD (100 µM), which can mimic corticothalamic excitatory transmission [63], induced a 
sustained, tonic spike firing pattern (top). Addition of propofol (3 µM) depressed firing (middle), accompanied by spontaneous 
IPSPs (sIPSPs). The suppression could be blocked by bicuculline (10 µM; bottom). B: segments marked with "i, ii, iii" in A are 
expanded to view sIPSPs. Spikes are truncated for clarity. Note that few sIPSPs are seen prior to propofol application (i), small 
sIPSPs (< 6.5 mV, ii) and large sIPSPs (6.5 – 16.5 mV, iii) are observed following propofol application. Scale: 20 mV, 200 ms for i, 
20 mV, 100 ms for ii and iii. C: time course histogram for group data (n = 8) showing propofol suppression of trans-ACPD-
induced tonic spike firing rate. Arrows indicate the onset and duration of propofol application at given concentrations. The 
suppression of propofol could be blocked by bicuculline. SE bars (0.5 – 2.2) are omitted for clarity. D: bar graph of cumulative 
data indicates that propofol (prop) hyperpolarized the membrane potential (MP) and this effect was reversed during addition of 
bicuculline (+bic). *: P < 0.01, one way ANOVA with Tukey test, propofol vs. control, propofol vs. propofol + bicuculline. n = 
8 – 12/each.
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glutamate receptor agonist trans-ACPD was used as a
pharmacological means to mimic this firing pattern [63].
We found that propofol also inhibited ACPD-evoked fir-
ing through a shunting mechanism, and cessation of spike
firing in VB neurons was companied by the appearance of
spontaneous IPSPs (Fig. 4). The occurrence of sIPSPs
strongly suggests that propofol potentiated GABAergic
inhibitory input from RTN to VB [77]. Coherent thalamo-
cortical activity during the waking state appears to be
essential for conscious experience [17,78], and propofol-
elicited shunting inhibition may disrupt such neuronal
activity, thereby producing the behavioral changes seen
during general anesthesia [79].
IPSPs can contribute to the sculpting of excitatory poten-
tials, and thereby modulate synaptic integration [80,81].
Such an effect is consistent with our observation propofol
produced a GABAA receptor-mediated decrease in tempo-
ral summation in VB neurons (Fig. 2). In addition, the
decrease in temporal summation in VB neurons in
response to corticothalamic stimulation parallels the fail-
ure of spike transfer shown in Fig. 3. The failure of spike
Propofol-potentiated IPSCs are mediated by GABAA receptor chloride channels Figure 5
Propofol-potentiated IPSCs are mediated by GABAA receptor chloride channels. A: GABAA IPSCs were evoked in 
a VB relay neuron in a horizontal slice by RTN stimulation (50 µA, 180 µs, every 15 s) in the presence of the GABAB antagonist 
2-OH saclofen (100 µM). The membrane potential was clamped at -60 mV. Synaptic currents were potentiated by propofol (3 
µM, 10 min). Overlay showing current amplitude in the absence (control) and presence of propofol. Each trace is an average of 
10 sweeps. B: normalized traces showing that propofol prolonged the decay time of IPSCs. C: propofol-potentiated eIPSCs 
could be abolished by picrotoxin (100 µM). D-F: bar graphs of pooled data indicate that propofol increased eIPSC amplitude, 
decay time, and charge transfer in a concentration-dependent manner. *: P < 0.05, one-way ANOVA, vs. control, n = 20.
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transfer in VB neurons following propofol application
supports the observation that feedback inhibition gates
spike transmission in hybrid thalamic circuits [82]. It is
unlikely that propofol directly suppressed glutamatergic
transmission because propofol, at the concentrations used
here (< 10 µM), has no effect on glutamate receptors
[65,66] or glutamatergic excitatory transmission [69].
GABAA receptors mediate the effect of propofol in VB 
neurons
Anesthetic suppression of excitatory responses may be
mediated by at least two distinct mechanisms: enhance-
ment of GABAergic transmission and direct suppression
of glutamatergic transmission. Our results showed that
there was strong evidence for shunting inhibition of syn-
aptic temporal summation (Fig. 2) and trans-ACPD-
evoked spike firing rate (Fig. 4), as a marked decrease in
apparent input resistance was observed during propofol
application. In addition, propofol caused a prolonged
hyperpolarization of the membrane potential while
inhibiting ACPD-evoked spike firing (Fig. 4), and the
hyperpolarization was reversed by bicuculline or picro-
toxin. The data strongly suggested that a tonic GABAA
receptor current may be involved in mediating the inhibi-
tion during propofol application, consistent with previ-
ous observations [83,84]. The GABAA receptor δ subunit is
expressed in VB [57], and likely contributes to an extrasy-
naptic pentameric receptor with an α4βδ configuration
[48,53,54]. Propofol potentiates δ subunit-containing
GABAA receptors when co-expressed with an α4, but not
α6, subunit [30,31]. Thus, the propofol-induced hyperpo-
larization of the cell membrane observed here is consist-
ent with its potentiation of extrasynaptic GABAA receptors.
Our data also provide evidence for propofol potentiation
of the GABAA receptor chloride channel-mediated phasic
currents, as propofol markedly increased picrotoxin-sensi-
tive IPSC amplitude, decay time, and charge transfer (Fig.
5). In addition to a pool of synaptic receptors containing
an α1 subunit that mediates fast IPSCs [44-47], α4 subu-
nit-containing receptors accounts for ~30% of the total
GABAA receptor population in the thalamus [48,49]. α4-
containing receptors are recognized by [3H]Ro15-4513
[48], indicating the presence of a γ2 subunit, and are
expressed synaptically [40,50]. Therefore, the pool of syn-
aptic GABAA receptors expressed by VB neurons is hetero-
geneous, consisting primarily of α1- and α4-subunit
containing receptors. Propofol markedly increased IPSC
amplitude, suggesting potentiation of synaptic receptors
containing either an α1 or α4 subunit [30,35]. These
receptors are likely to contain a β2 subunit as this subunit
contributes to propofol-induced potentiation of GABA-
evoked currents [85]. Finally, propofol-increased IPSC
decay time suggested that the γ subunit might be involved,
since propofol prolonged the deactivation time in recep-
tors expressed in HEK cells containing a γ2L subunit [31].
These data strongly support the conclusion that propofol
caused shunting inhibition by enhancing GABAA receptor-
mediated chloride conductance in VB neurons through
both synaptic and extrasynaptic receptors.
Conclusions
The GABAergic general anesthetic propofol, at clinically
relevant concentrations, markedly suppressed excitability
and synaptic responsiveness to corticothalamic activation
in thalamocortical relay neurons in VB. Propofol
enhancement of postsynaptic GABAA  receptor-function
on VB neurons resulted in shunting inhibition of
excitatory input. Recent clinical findings
[22,24,25,79,86,87] and in vivo electrophysiological evi-
dence [28] have all suggested that thalamocortical circuits
may constitute a strategic target for some general anesthet-
ics including propofol. Our results support that hypothe-
sis, and clearly establish the link between propofol-
mediated inhibition of corticothalamic activation of VB
neurons and propofol-enhanced GABAA  receptor
function.
Methods
Brain slice preparation
Experiments were performed in accordance with institu-
tional and federal guidelines. Thalamocortical (TC) slices
were prepared as described [88] with a slight modifica-
tion. Briefly, mice (C57BL/6, P25–55) were anesthetized
by halothane and decapitated. The head was immediately
submerged in ice-cold carbogenated (95% O2/5% CO2)
slicing solution, and the brain was rapidly dissected out.
The rostral portion of the brain was cut at 45° or 55°; the
rostral end of the brain block was glued to a homemade
platform. Slices (240 or 300 µm) were cut on a microslicer
(Leica VT 1000S, Wetzlar, Germany) using a sapphire
blade (Leica) to yield smooth-surface slices, gently rinsed
once in cold artificial cerebrospinal fluid (ACSF) bath
solution, and incubated in carbogenated ACSF at 34°C for
1 hr for recovery and at 24°C for at least another 1 hr
before use. For horizontal slices, the brain was sagittally
cut into two halves along the midline; 240 µm-thick slices
containing both VB and RTN were prepared. Experiments
were generally performed on TC slices, except those with
RTN stimulation that were carried out in horizontal slices.
Electrophysiology
Current-clamp recordings were performed at 35°C. Slices
were perfused with carbogenated ACSF; neurons were vis-
ualized and identified using a Zeiss Axioskop (Jena, Ger-
many) equipped with a 2.5 × objective and 40 × water
immersion objective with a 2.4 mm working distance and
IR-DIC optics. The resistance of the pipette was 3.5–6 MΩ
when filled with internal solution. Tight seal (> 2 GΩ) was
achieved by application of a small negative pressure, usingMolecular Pain 2005, 1:2 http://www.molecularpain.com/content/1/1/2
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a 1 ml-syringe. Access resistance (Ra) ranged from 10–14
MΩ, and was compensated by up to 60%; data were dis-
carded if Ra > 15 MΩ. Input resistance was measured at a
holding membrane potential level close to resting mem-
brane potential (RMP) from the voltage response elicited
by a small current pulse (-60 pA). Only neurons that
showed a stable RMP negative to -60 mV, action potential
(AP) overshoot of > 10 mV and Ri > 150 MΩ (in current-
clamp mode) were selected for study. Although cells so
selected generally showed stable data records for up to
240 min, pharmacological tests were completed within 90
min to minimize the variation of responses; only one
experiment per slice was performed. Liquid junction
potentials (11–12.2 mV) for intracellular and bath solu-
tions were calculated by Junction Potential Calculator
(Clampex 8, Axon Instruments, Union City, CA), and cor-
rected online or offline. Membrane voltage was filtered at
5 kHz, membrane current at 2 kHz and then digitized at
10 kHz using an Axopatch 200A amplifier connected to a
DigiData 1200 interface (Axon).
Extracellular electrical stimulation
To stimulate CT fibers, a concentric bipolar tungsten elec-
trode (FHC Inc., Bowdoinham, ME) was placed in either
layer VI of the barrel cortex or the white matter in TC slices
[60]. Single pulses or train pulses were delivered using a
Master-8 pulse generator (A.M.P.I., Jerusalem, Israel) con-
trolled by a PC and a constant current stimulus isolator
(World Precision Instruments, Sarasota, FL). Responses
were considered monosynaptic if the latency jitter was less
than 0.4 ms and their rise times were consistent from trial
to trial (3 trials). Latency was calculated from start of stim-
ulus to onset of response. To confirm that the effects of
propofol were GABAA receptor mediated, responses were
blocked by a GABAA receptor antagonist (bicuculline 10
µM or gabazine 10 µM) or Cl- channel blocker (picrotoxin
100 µM). To evoke IPSCs, the stimulation electrode was
placed in RTN, and synaptic currents were recorded in the
presence of the GABAB receptor antagonist 2-OH saclofen
(100 µM), and in some cases the non-NMDA receptor
antagonist CNQX (20 µM) and NMDA receptor antago-
nist D-AP5 (40 µM) were added. CNQX and D-AP5 were
also used to block evoked excitatory postsynaptic poten-
tials (EPSPs) and the Na+ channel blocker tetrodotoxin
(500 nM) was used to block evoked action potentials.
Drug application
Drugs were applied by bath superfusion (unless otherwise
noted) for at least 10 min prior to data collection using
polytetrafluoroethylene (Teflon®) tubing and connectors;
solution flow rates were 3 ml/min. Propofol was freshly
prepared in DMSO and diluted with ACSF to clinically rel-
evant concentrations (0.3 – 3 µM); the final concentration
of DMSO was 0.01%, which had no effects on the cells
examined. The concentration range was selected based on
the fact that a free aqueous concentration of ~2 µM is
required to inhibit a response to a painful stimulus in
50% of test mammalian subjects [89].
Solutions
Slicing solution contained (in mM): 2.5 KCl, 24 NaHCO3,
1.25 NaH2PO4, 234 sucrose, 11 glucose, 10 MgSO4, and
0.5 CaCl2. ACSF bath solution contained (in mM): 124
NaCl, 26 NaHCO3,2.5 KCl, 1.25 NaH2PO4, 1.2 MgCl2,
and 2 CaCl2 and 11 glucose. Intracellular solution con-
tained (in mM): 130 K-gluconate, 5 NaCl, 2 MgCl2, 10
HEPES, 0.5 EGTA, 2 ATP-K, 0.3 GTP-Na, pH adjusted to
7.25 with KOH. K-gluconate was used because the
impermeant ion gluconate does not contribute to anes-
thetic-induced changes in RMP or I-V relationship [90].
Voltage-clamp recordings of inhibitory postsynaptic cur-
rents (IPSCs) were made at 25°C, using a Cs+-based inter-
nal solution [91]. The bath solution for voltage-clamp
contained (in mM): 117 NaCl, 25 NaHCO3, 3.6 KCl, 1.2
NaH2PO4, 1.2 MgCl2, and 2.5 CaCl2 and 11 glucose;
osmolarity was adjusted to 300 mOsm with sucrose. All
bath solutions were freshly prepared on the same experi-
mental day.
Intracellular biocytin filling
Neurons from 30 mice were intracellularly filled with bio-
cytin (0.5% in the pipette solution). After recording, slices
were fixed for 24–72 hrs in phosphate buffer (PB) solu-
tion containing 4% paraformaldehyde, transferred to
20% sucrose solution in 0.1 M PB and re-sectioned to 60
-100  µm. After endogenous peroxidases were blocked
with phosphate-buffered 3% H2O2, the slices were incu-
bated with biotinylated horseradish peroxidase conju-
gated to avidin (ABC-Elite, Vector Labs, Burlingame, CA),
washed and incubated with DAB for 15 min. Filled neu-
rons were visualized and reconstructed.
Chemicals
Compounds from Tocris Cookson (Ellisville, MO) were:
(+) bicuculline, picrotoxin, gabazine, 2-OH saclofen,
(2S)-3-[[(1S)-1-(3,4-dichlorophenyl) ethyl] amino-2-
hydroxypropyl] (phenylmethyl) phosphinic acid
(CGP55845), 6-cyano-7-nitroquinoxaline-2, 3-dione
(CNQX), D-2-amino-5-phosphopentanoic acid (D-AP5),
(±)1-aminocyclopentane-trans-1, 3-dicarboxylic acid
(trans-ACPD). Tetrodotoxin (TTX) was from Alomone
Labs (Jerusalem, Israel), and propofol was from Aldrich
(Milwaukee, WI).
Data and statistical analysis
Membrane voltages and currents were analyzed using
both Clampfit 9.0 and MiniAnalysis 6 (Synaptosoft, Deca-
tur, GA). To analyze temporal summation containing five
responses, the peak of the first and fifth responses were
measured from baseline and expressed as ∆V1 and ∆V5,Molecular Pain 2005, 1:2 http://www.molecularpain.com/content/1/1/2
Page 12 of 14
(page number not for citation purposes)
respectively; responses were calculated as: % increase =
[(∆V5 / ∆V1) - 1] × 100. Temporal summation was defined
as % increase in depolarization occurring at the soma dur-
ing a train [92]. Statistical analyses were performed with
Sigmastat V 3.0 (SPSS, Chicago, IL) using t-test or one-way
ANOVA. Data were expressed as means ± SE.
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